<DOC>
	<DOCNO>NCT00583557</DOCNO>
	<brief_summary>This continuation trial LymphoStat-B™ evaluate long-term safety subject Rheumatoid Arthritis complete study LBRA01 benefit treatment .</brief_summary>
	<brief_title>A Continuation Trial Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01</brief_title>
	<detailed_description>This multi-center , open label , continuation trial LymphoStat-B™ Rheumatoid Arthritis ( RA ) subject achieve least ACR20 response Phase 2 study LBRA01 ( NCT00071812 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Primary 1 . Have complete LBRA01 trial . 2 . Have achieve least ACR20 response end LBRA01 . Primary 1 . Have switch NSAIDs due worsen RA disease activity , use 10 mg/day oral prednisone , give corticosteroid injection last 30 day LBRA01 . 2 . Required new DMARD ( otherwise exclude protocol LBRA01 ) replace ineffective one , additional DMARD ( exceed 2 DMARDs total ) within last 60 day LBRA01 . 3 . Used prohibited medication participation LBRA01 . These medication include follow : Other investigational agent . Biologic response modifier Cyclophosphamide . Corticosteroid injection ( except 1 injection 40 mg prednisone inflame joint intramuscularly every 6 month ) . 2 new DMARDs . 1 new DMARD plus high dose prednisone &gt; 10 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
</DOC>